University of Montreal Health Centre is about to start An Ex-Vivo Human Lung Model Study
The Centre hospitalier de l'Université de Montréal (CHUM) is conducting the clinical trial Evaluation of Deployment Capability and Accuracy of an Outside the Scope (OTS), Detachable Catheter System for Ablation of Peripheral Lung Lesions: An Ex-Vivo Human Lung Model Study.
A novel OTS detachable probe system carried outside and along the flexible bronchoscope has been developed. Using this novel system, the operator can deploy the probe in the target bronchus and lesion and completely detach the scope from the probe.
Lung ablative therapies have growing interest in the treatment of early-stage primary lung cancer in surgical high-risk patients and as part of multimodal treatment in patients with large lesions or metastatic malignant disease in the lungs. Endobronchial ablative strategies allow deliver y of these therapies through a natural orifice and minimally invasive approach, potentially improving safety and reducing related morbidity. Application and deployment of this system allows the operator to have constant control of the airway, preventing life-threatening hemoptysis and other complications. We hypothesize that this novel detachable OTS system can be successfully deployed in the peripheral parenchymal target with potential clinical applications in the near future.
Patients who follow surgery for the removal of diseased lungs before being submitted to a bilateral lung transplant can be enrollrd into this study.
The primary outcome measure accuracy of the deployment method.
The Centre hospitalier de l'Université de Montréal (CHUM, University of Montreal Health Centre) is one of two major healthcare networks in the city of Montreal, Quebec. It is a teaching institution affiliated with the French-language Université de Montréal. The CHUM is one of the largest hospitals in Canada; a public not-for-profit corporation, it receives most of its funding from Quebec taxpayers through the Ministry of Health and Social Services as mandated by the Canada Health Act. The CHUM's primary mission is to provide inpatient and ambulatory care to its immediate urban clientele and specialized and ultraspecialized services to the broader metropolitan and provincial population. Its mandate also includes pure and applied research, teaching, and the evaluation of medical technology and best healthcare practices. Every year, more than 500,000 patients are admitted for care at the CHUM.
The location of the study is as follows (further details can be found here https://ichgcp.net/clinical-trials-registry/NCT04722432) Montreal, Canada.
